Navigation Links
Neighborhood Smiles of La Crosse Takes a Bold New Approach to the Tooth Decay Epidemic
Date:4/10/2013

La Crosse, Wisconsin (PRWEB) April 10, 2013

Dental decay is the number one chronic disease affecting American youth; surpassing both obesity and asthma. For Neighborhood Smiles of LaCrosse those statistics are no longer daunting. The doctors have taken the top caries research in the world and implemented a cavity prevention program developed by CariFree that is shown to decrease incidents of tooth decay by up to 74%. The system is known as CAMBRA or Caries Management by Risk Assessment. Dr's Spitzer and Dommer say: "We base all treatment plans on individual Risk Factors. Patients with high risk to decay are those on medications which cause dry mouth, soda drinkers, and patients with acidic bacteria. With CariFree, we can combat these acid attacks, and sometimes reverse the effects of early decay. Now that is exciting!"

CAMBRA is rooted in a medical model of risk assessment. It requires the dental professional to assess each and every patient’s risk factors for the disease and then develop a personalized treatment plan to systematically lower their risk. The CariFree diagnostic tools leverage biofilm testing (to determine the levels of cavity-causing bacteria in the patient’s mouth) as well as a risk assessment questionnaire to determine the overall statistical probability a patient will develop new cavities over the next 12 months. Never before has such predictive information been available. Patients can then measurably lower their risk for decay by utilizing professional products and behavior modification.

Patients can expect the entire process to take a few minutes i
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BIOWATER Wastewater Treatment Package Plant Arrives in Residential Neighborhoods
2. Neighborhood Smiles Launches a Groundbreaking Cavity Prevention Program for Their Patients
3. Neighborhood Smiles of Green Bay Offers a New Approach to the Cavity Epidemic
4. New Kit Takes the Uncertainty Out of Lymphoma Diagnosis
5. Terminator-style info-vision takes step towards reality
6. Arteriocyte Takes the Lead in Promoting Building Future Pipeline of Women in STEM Career Fields
7. Quammen Health Care Consultants Takes Over Information Technology Reins at Faith Regional Health Services
8. Michael A. Marletta Takes Office as New President of Scripps Research Institute
9. UK takes the lead in redefining the kilogram
10. Big Ideas, Big Stakes
11. Research breakthrough takes supercomputing out of the lab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... CITY, Kan. , July 30, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today announced that its strategic ... from a dose confirmation study of AT-016, an ... Aratana for the treatment of osteoarthritis pain in ...
(Date:7/30/2015)... July 30, 2015 HIGHLIGHTS:Q2 2015 ... 2014) , Reported sales were $697 million compared ... Sales grew organically by 8%, and changes in foreign ... increased sales by 1%. , By business unit, ... Applied and 11% in SAFC Commercial. , Reported ...
(Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
(Date:7/29/2015)... Japan (Q2 2015: +14% CER / 20% of sales) ... in China , as well as solid contributions from Korea, ... Europe / Middle East / ... in Germany , Turkey and the ... 49% of sales) grew 11%, excluding U.S. HPV sales, on demand across all ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
... ISIS ) announces the following webcast: , , ... of a, microRNA, ... 1, 2008, at 8:30 a.m. ET / 5:30 a.m. PT, Where: ... Simply log onto our website listed above., , ...
... in the research of vein treatment methods led by Dr. Sinjae Hyun, ... new medical device, which he will present this summer to his research ... ... A gift from a California company aided in the research of ...
... Dec. 1 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... and Drug,Administration (FDA) has accepted for filing and ... supplemental Biologics License Application,(sBLA) for use of Zevalin(R) ... B-cell non-Hodgkin,s lymphoma who achieve,a response to first-line ...
Cached Biology Technology:Gift Aids Professor's Research into Vein Treatment 2Gift Aids Professor's Research into Vein Treatment 3Gift Aids Professor's Research into Vein Treatment 4FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 2FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 3FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 4FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 5
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/23/2015)... Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... of 2015 was $4.5 million, a decrease of 33% compared ... income in the second quarter of 2015 was $0.3 million, ... or $0.04 per diluted share, in the same period a ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... search for better ways to target anticancer drugs to ... nanoparticles called buckyballs might be used to significantly boost ... In research due to appear in an upcoming issue ... and The University of Texas M. D. Anderson Cancer ...
... the National Institute of Standards and Technology (NIST) have ... for small numbers of biomolecules. The unusually simple containment ... and perhaps lead to the development of molecule-sorting devices ... research. The work was reported in the July 3 ...
... world soon could be made completely flood-tolerant because ... in collaboration with scientists at UC Davis and ... By gradually introducing into California rice "submergence tolerance," ... flood conditions, the researchers show how potentially any ...
Cached Biology News:Buckyballs boost antibody's chemotherapy payload 2'Micro-boxes' of water used to study single molecules 2Researchers develop flood-tolerant California rice 2Researchers develop flood-tolerant California rice 3
... in conjuction with Annexin V-FITC to distinguish ... of apoptosis (Annexin V positive, PI negative) ... of apoptosis or already dead (Annexin V-FITC ... the orange range of the spectrum using ...
... RPMI 1640 with 2 mM L-glutamine and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... software package that provides crystallographers with ... buffer creation, set-up of experimental conditions ... The software helps crystallographers through the ... crystallography: Design of ...
... antibiotic-based selection system for recombinant identification. Recombinant ... the need for costly color screening. This ... 100% accuracy in recombinant selection. pLivSelect is ... picking. This cloning kit can be used ...
Biology Products: